




RealRate

PHARMACEUTICAL 2018

ChemoCentryx Inc.
Rank 164 of 342





PHARMACEUTICAL 2018

ChemoCentryx Inc.
Rank 164 of 342



The relative strengths and weaknesses of ChemoCentryx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ChemoCentryx Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 79% points. The greatest weakness of ChemoCentryx Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 103%, being 57% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	179,830
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,937
Liabilities, Non-Current	251
Other Assets	8,288
Other Compr. Net Income	-69
Other Expenses	0
Other Liabilities	76,873
Other Net Income	1,366
Other Revenues	82,497
Property and Equipment	1,210
Research and Development	49,495
Selling, General and Administrative Expense	16,509

Output Variable	Value in 1000 USD
Assets	189,328
Liabilities	110,061
Expenses	66,004
Revenues	82,497
Stockholders Equity	79,267
Net Income	17,859
Comprehensive Net Income	17,824
Economic Capital Ratio	103%